Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenomics J. 2012 Jun;12(3):197-204. doi: 10.1038/tpj.2011.1. Epub 2011 Feb 15.

Survey of US public attitudes toward pharmacogenetic testing.

Author information

1
Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA. susanne.haga@duke.edu

Abstract

To assess public attitudes and interest in pharmacogenetic (PGx) testing, we conducted a random-digit-dial telephone survey of US adults, achieving a response rate of 42% (n=1139). Most respondents expressed interest in PGx testing to predict mild or serious side effects (73±3.29 and 85±2.91%, respectively), guide dosing (91%) and assist with drug selection (92%). Younger individuals (aged 18-34 years) were more likely to be interested in PGx testing to predict serious side effects (vs aged 55+ years), as well as Whites, those with a college degree, and who had experienced side effects from medications. However, most respondents (78±3.14%) were not likely to have a PGx test if there was a risk that their DNA sample or test result could be shared without their permission. Given differences in interest among some groups, providers should clearly discuss the purpose of testing, alternative testing options (if available) and policies to protect patient privacy and confidentiality.

PMID:
21321582
PMCID:
PMC3139751
DOI:
10.1038/tpj.2011.1
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center